Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Commentary

Improved blood tests for cancer screening: general or specific?

Author: Ian A Cree

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Diagnosis of cancer at an early stage leads to improved survival. However, most current blood tests detect single biomarkers that are of limited suitability for screening, and existing screening programmes look only for cancers of one particular type. A new approach is needed. Recent developments suggest the possibility of blood-based screening for multiple tumour types. It may be feasible to develop a high-sensitivity general screen for cancer using multiple proteins and nucleic acids present in the blood of cancer patients, based on the biological characteristics of cancer. Positive samples in the general screen would be submitted automatically for secondary screening using tests to help define the likelihood of cancer and provide some indication of its type. Only those at high risk would be referred for further clinical assessment to permit early treatment and mitigate potential overdiagnosis. While the assays required for each step exist, they have not been used in this way. Recent experience of screening for breast, cervical and ovarian cancers suggest that there is likely to be widespread acceptance of such a strategy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008, 149: 441-450. W81CrossRefPubMedPubMedCentral Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008, 149: 441-450. W81CrossRefPubMedPubMedCentral
2.
go back to reference Vinnicombe S, Pinto Pereira SM, McCormack VA, Shiel S, Perry N, Dos Santos Silva IM: Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. Radiology. 2009, 251: 347-358. 10.1148/radiol.2512081235.CrossRefPubMed Vinnicombe S, Pinto Pereira SM, McCormack VA, Shiel S, Perry N, Dos Santos Silva IM: Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. Radiology. 2009, 251: 347-358. 10.1148/radiol.2512081235.CrossRefPubMed
3.
go back to reference Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, Gray A, Sadique Z, Moss S, MAVARIC Trial Study Group: MAVARIC: a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess. 2011, 15: iii-iv. ix-xi, 1-170CrossRefPubMed Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, Gray A, Sadique Z, Moss S, MAVARIC Trial Study Group: MAVARIC: a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess. 2011, 15: iii-iv. ix-xi, 1-170CrossRefPubMed
4.
go back to reference Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 337: a1754-10.1136/bmj.a1754.CrossRefPubMedPubMedCentral Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 337: a1754-10.1136/bmj.a1754.CrossRefPubMedPubMedCentral
5.
go back to reference Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW: Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 103: 520-523. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW: Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 103: 520-523.
6.
go back to reference Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981, 68: 1331-1337. 10.1172/JCI110380.CrossRefPubMedPubMedCentral Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981, 68: 1331-1337. 10.1172/JCI110380.CrossRefPubMedPubMedCentral
7.
go back to reference Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009, 10: 327-340. 10.1016/S1470-2045(09)70026-9.CrossRefPubMed Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009, 10: 327-340. 10.1016/S1470-2045(09)70026-9.CrossRefPubMed
8.
go back to reference Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R: Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Int J Gynecol Cancer. 2011, 20: 1518-1524. Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R: Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Int J Gynecol Cancer. 2011, 20: 1518-1524.
9.
go back to reference Hanash SM, Baik CS, Kallioniemi O: Emerging molecular biomarkers: blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011, 8: 142-150. 10.1038/nrclinonc.2010.220.CrossRefPubMed Hanash SM, Baik CS, Kallioniemi O: Emerging molecular biomarkers: blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011, 8: 142-150. 10.1038/nrclinonc.2010.220.CrossRefPubMed
10.
go back to reference Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
11.
go back to reference Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K: New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005, 15 (Suppl 3): 274-281.CrossRefPubMed Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K: New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005, 15 (Suppl 3): 274-281.CrossRefPubMed
12.
go back to reference Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70: 8309-8318. 10.1158/0008-5472.CAN-10-1319.CrossRefPubMedPubMedCentral Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70: 8309-8318. 10.1158/0008-5472.CAN-10-1319.CrossRefPubMedPubMedCentral
14.
go back to reference Nordström A, Lewensohn R: Metabolomics: moving to the clinic. J Neuroimmune Pharmacol. 2010, 5: 4-17. 10.1007/s11481-009-9156-4.CrossRefPubMed Nordström A, Lewensohn R: Metabolomics: moving to the clinic. J Neuroimmune Pharmacol. 2010, 5: 4-17. 10.1007/s11481-009-9156-4.CrossRefPubMed
15.
go back to reference Johansson M, McKay JD, Rinaldi S, Wiklund F, Adami HO, Grönberg H, Kaaks R, Stattin P: Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate. 2009, 69: 1281-1291. 10.1002/pros.20972.CrossRefPubMed Johansson M, McKay JD, Rinaldi S, Wiklund F, Adami HO, Grönberg H, Kaaks R, Stattin P: Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate. 2009, 69: 1281-1291. 10.1002/pros.20972.CrossRefPubMed
16.
go back to reference Carbone A, Rodeck U, Mauri FA, Sozzi M, Gaspari F, Smirne C, Prati A, Addeo A, Novarino A, Robecchi A, Bertetto O, Emanuelli G, Bellone G: Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther. 2005, 4: 231-241. 10.4161/cbt.4.2.1476.CrossRefPubMed Carbone A, Rodeck U, Mauri FA, Sozzi M, Gaspari F, Smirne C, Prati A, Addeo A, Novarino A, Robecchi A, Bertetto O, Emanuelli G, Bellone G: Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther. 2005, 4: 231-241. 10.4161/cbt.4.2.1476.CrossRefPubMed
17.
go back to reference Ueno T, Toi M, Linder S: Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother. 2005, 59 (Suppl 2): S359-S362.CrossRefPubMed Ueno T, Toi M, Linder S: Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother. 2005, 59 (Suppl 2): S359-S362.CrossRefPubMed
18.
go back to reference Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N, Pakk C, Suzuki N, Sekiya S: Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumor Biol. 1995, 16: 345-352. 10.1159/000217951.CrossRef Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N, Pakk C, Suzuki N, Sekiya S: Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumor Biol. 1995, 16: 345-352. 10.1159/000217951.CrossRef
19.
go back to reference Wang J, Yi Y, Li B, Wang Z, Sun H, Zhang P, Huang W: CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma. Biomarkers. 2010, 15: 594-601. 10.3109/1354750X.2010.504308.CrossRefPubMed Wang J, Yi Y, Li B, Wang Z, Sun H, Zhang P, Huang W: CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma. Biomarkers. 2010, 15: 594-601. 10.3109/1354750X.2010.504308.CrossRefPubMed
20.
go back to reference Chen Z, Feng J, Buzin CH, Liu Q, Weiss L, Kernstine K, Somlo G, Sommer SS: Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One. 2009, 4: e7220-10.1371/journal.pone.0007220.CrossRefPubMedPubMedCentral Chen Z, Feng J, Buzin CH, Liu Q, Weiss L, Kernstine K, Somlo G, Sommer SS: Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One. 2009, 4: e7220-10.1371/journal.pone.0007220.CrossRefPubMedPubMedCentral
21.
go back to reference Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C: Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2011, 120: 461-467.CrossRef Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C: Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2011, 120: 461-467.CrossRef
22.
go back to reference Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, Chyczewski L, Kulikowski M: Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 2010, 127: 612-621. 10.1002/ijc.25077.CrossRefPubMed Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, Chyczewski L, Kulikowski M: Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 2010, 127: 612-621. 10.1002/ijc.25077.CrossRefPubMed
23.
go back to reference Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V: Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer. 2010, 116: 1674-1680. 10.1002/cncr.24893.CrossRefPubMed Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V: Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer. 2010, 116: 1674-1680. 10.1002/cncr.24893.CrossRefPubMed
24.
go back to reference Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2003, 3: 109-113.CrossRef Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2003, 3: 109-113.CrossRef
25.
26.
go back to reference Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel DM: Exosomes: fit to deliver small RNA. Commun Integr Biol. 2010, 3: 447-450. 10.4161/cib.3.5.12339.CrossRefPubMedPubMedCentral Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel DM: Exosomes: fit to deliver small RNA. Commun Integr Biol. 2010, 3: 447-450. 10.4161/cib.3.5.12339.CrossRefPubMedPubMedCentral
28.
go back to reference Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS: A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010, 14: 528-552.PubMed Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS: A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010, 14: 528-552.PubMed
29.
go back to reference Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rüegg C: Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010, 30: 529-545.CrossRefPubMed Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rüegg C: Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010, 30: 529-545.CrossRefPubMed
30.
go back to reference Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol. 2009, 115: 112-120. 10.1016/j.ygyno.2009.06.031.CrossRefPubMedPubMedCentral Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol. 2009, 115: 112-120. 10.1016/j.ygyno.2009.06.031.CrossRefPubMedPubMedCentral
31.
go back to reference Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DSB: Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res. 2007, 13: 4105-4110. 10.1158/1078-0432.CCR-07-0419.CrossRefPubMed Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DSB: Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res. 2007, 13: 4105-4110. 10.1158/1078-0432.CCR-07-0419.CrossRefPubMed
32.
go back to reference Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA: Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008, 14: 985-990. 10.1038/nm.1789.CrossRefPubMed Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA: Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008, 14: 985-990. 10.1038/nm.1789.CrossRefPubMed
33.
go back to reference Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DSB: Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci. 2008, 1137: 171-174. 10.1196/annals.1448.011.CrossRefPubMed Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DSB: Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci. 2008, 1137: 171-174. 10.1196/annals.1448.011.CrossRefPubMed
34.
go back to reference Moreira VG, Prieto B, Rodríguez JS, Alvarez FV: Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem. 2010, 47: 253-258. 10.1258/acb.2010.009173.CrossRefPubMed Moreira VG, Prieto B, Rodríguez JS, Alvarez FV: Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem. 2010, 47: 253-258. 10.1258/acb.2010.009173.CrossRefPubMed
35.
go back to reference Zhong XY, von Mühlenen I, Li Y, Kang A, Gupta AK, Tyndall A, Holzgreve W, Hahn S, Hasler P: Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem. 2007, 53: 1609-1614. 10.1373/clinchem.2006.084509.CrossRefPubMed Zhong XY, von Mühlenen I, Li Y, Kang A, Gupta AK, Tyndall A, Holzgreve W, Hahn S, Hasler P: Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem. 2007, 53: 1609-1614. 10.1373/clinchem.2006.084509.CrossRefPubMed
36.
go back to reference Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, LIPID Study Investigators: Monitoring cholesterol levels: measurement error or true change?. Ann Intern Med. 2008, 148: 656-661.CrossRefPubMed Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, LIPID Study Investigators: Monitoring cholesterol levels: measurement error or true change?. Ann Intern Med. 2008, 148: 656-661.CrossRefPubMed
37.
go back to reference Künzli BM, Friess H, Shrikhande SV: Is laparoscopic colorectal cancer surgery equal to open surgery? An evidence based perspective. World J Gastrointest Surg. 2010, 2: 101-108. 10.4240/wjgs.v2.i4.101.CrossRefPubMedPubMedCentral Künzli BM, Friess H, Shrikhande SV: Is laparoscopic colorectal cancer surgery equal to open surgery? An evidence based perspective. World J Gastrointest Surg. 2010, 2: 101-108. 10.4240/wjgs.v2.i4.101.CrossRefPubMedPubMedCentral
38.
go back to reference Green S, Tawil A, Barr H, Bennett C, Bhandari P, Decaestecker J, Ragunath K, Singh R, Jankowski J: Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. Cochrane Database Syst Rev. 2009, 2: CD007334-PubMed Green S, Tawil A, Barr H, Bennett C, Bhandari P, Decaestecker J, Ragunath K, Singh R, Jankowski J: Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. Cochrane Database Syst Rev. 2009, 2: CD007334-PubMed
39.
go back to reference Hoff G, Dominitz JA: Contrasting US and European approaches to colorectal cancer screening: which is best?. Gut. 2010, 59: 407-414. 10.1136/gut.2009.192948.CrossRefPubMed Hoff G, Dominitz JA: Contrasting US and European approaches to colorectal cancer screening: which is best?. Gut. 2010, 59: 407-414. 10.1136/gut.2009.192948.CrossRefPubMed
40.
go back to reference Gøtzsche PC, Nielsen M: Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011, 1: CD001877-PubMed Gøtzsche PC, Nielsen M: Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011, 1: CD001877-PubMed
41.
go back to reference Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009, 112: 40-46. 10.1016/j.ygyno.2008.08.031.CrossRefPubMed Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009, 112: 40-46. 10.1016/j.ygyno.2008.08.031.CrossRefPubMed
42.
go back to reference Pirmohamed M: Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther. 2010, 88: 862-866. 10.1038/clpt.2010.245.CrossRefPubMed Pirmohamed M: Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther. 2010, 88: 862-866. 10.1038/clpt.2010.245.CrossRefPubMed
Metadata
Title
Improved blood tests for cancer screening: general or specific?
Author
Ian A Cree
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-499

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine